Health Care · Services-Home Health Care Services

OPCH Option Care Health, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 1014739129 filings
Russell 2000

OPCH at a glance

Option Care Health, Inc. (OPCH, SEC CIK 1014739) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and Form 4 insider filings as recently as November 12, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Option Care Health, Inc. (OPCH) reported revenue of $5.6 billion (up 15.0% from FY2024) and net income of $207.6 million. Diluted EPS was $1.27.
  • As of September 30, 2026, 32 institutional investment managers tracked by SignalX reported holding Option Care Health, Inc. (OPCH) shares worth $1.5 billion in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Pate R Carter on November 11, 2026 of 400 shares at $31.65 per share.
  • In the last 90 days, OPCH insiders reported 0 open-market purchases ($0) and 2 open-market sales ($205K) on Form 4, a net sale of $205K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$5.6B
+15.0% vs prior year
Insiders · 90 days
0 buys · 2 sells
Net −$205K
13F holders
32 funds
$1.5B · +1 vs prior quarter
Latest 8-K
Nov 4, 2026
Item 2.02

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Core business: Largest independent provider of home and alternate site infusion therapy via 196 locations in 43 states, serving complex chronic conditions
  • New emphasis: Expansion of ambulatory infusion suites to 109 standalone locations, including 27 with advanced practitioner capabilities
  • Strategic position: Strengthened national presence with integrated sales targeting managed care, health systems, and drug manufacturers for new product launches
  • Quantitative metric: Employee count rose to 6,528 full-time and 1,738 part-time as of Dec 31, 2025, including ~2,700 nursing staff
  • Noteworthy fact: Received multiple national accreditations (ACHC, PCAB, ASHP, URAC) underscoring quality and compliance in infusion services

Management Discussion & Analysis

  • Revenue $5.65B, up 13.0% YoY from $5.00B driven by mid-teens growth in acute therapies and low double-digit chronic growth
  • Operating margin declined to 6.0% from 6.4%; gross margin fell to 19.3% from 20.3% due to therapy mix and biosimilar adoption
  • Best segment: Acute therapies with mid-teens revenue growth; Worst: Chronic therapies with higher cost mix including rare/orphan therapies
  • Operating cash flow $258M down $65M; investing cash outflow $161M up $125M due to Intramed Plus acquisition; financing cash outflow $277M up $59M driven by $310M stock repurchase
  • Management expects $25M-$35M negative gross profit impact in 2026; secured credit facility amendments lowered interest rate and extended maturities supporting liquidity

AI summary of the OPCH 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • Newly added merger risk: October 5, 2026 Merger Agreement created approval and closing uncertainties
  • Regulatory risk: HSR Act and healthcare regulatory approvals could delay or prevent consummation
  • Operational risk: Merger restrictions may limit debt, acquisitions, capital expenditures, and material contracts
  • Financial risk: Termination under specified circumstances could require approximately $145.96 million payment
  • Legal risk: Stockholder litigation could enjoin or delay the Merger and divert management attention

Management Discussion & Analysis

  • Q3 revenue $1,493.5M, up 4.1% from $1,435.0M YoY, driven by acute therapy growth
  • Gross margin 19.1% vs 19.0% YoY; operating margin 6.0% vs 5.9%
  • Acute therapies best performer, high-single-digit growth; CID weakest, declining from attrition and unfavorable mix
  • Operating cash flow $286.2M vs $222.6M; cash $299.1M vs $232.6M at December 31, 2025
  • CID headwinds expected to reduce 2026 gross profit by approximately $55M; merger expected to close first half of 2027

AI summary of the OPCH 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 4, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 financial results announced by Option Care Health on November 4, 2026
  • Detailed quarterly figures and management commentary in Exhibit 99.1

Item EX-99.1: Item EX-99.1

  • Q3 revenue $1,493.5M, up 4.1%, with GAAP net income $57.4M, up 10.8%
  • Diluted EPS $0.38, up 18.8%, while adjusted EPS reached $0.49, up 8.9%
Filed Oct 6, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • CD&R and McKesson agreed to acquire Option Care Health for $32.05 per share, valuing the company at approximately $5.8 billion
  • Offer represents an approximately 37% premium to OPCH’s October 5, 2026 closing price, providing immediate cash value to shareholders

Item 1.01: Entry into a Material Definitive Agreement

  • Acquisition agreed at $32.05 cash per share, subject to stockholder approval and regulatory clearances
  • CD&R and McKesson investor group financing includes $2.873B equity commitments and up to $3.15B debt

Item 7.01: Regulation FD Disclosure

  • Option Care Health, CD&R and McKesson announced entry into a merger agreement
  • Merger agreement signals a potentially transformative ownership change for Option Care Health
Filed Jul 29, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q2 2026 financial results released July 29, 2026, providing investors the company’s latest operating update
  • Exhibit 99.1 contains the substantive results, including GAAP figures and non-GAAP reconciliations

Item EX-99.1: Item EX-99.1

  • Q2 revenue $1.442B, up 1.9%; GAAP net income $53.9M, up 6.7%
  • Adjusted EBITDA $117.5M, up 3.0%; adjusted diluted EPS $0.45, up 9.8%

AI summaries of OPCH 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for OPCH

Don't miss the next OPCH filing

  • Alerts as it files. A push when OPCH files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut OPCH, by share count.
  • Ask anything. An AI agent that reads every OPCH filing and answers with sources.

OPCH alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Pate R CarterSellNov 11, 2026$31.65
Pate R CarterSellNov 10, 2026$31.65
Bhatia PrateekAJul 6, 2026-
Bhatia PrateekAJul 6, 2026-
Deckmann NatashaAMay 20, 2026$22.23
Bodem Barbara W.AMay 20, 2026-
BRANDT ERICAMay 20, 2026-
KRAEMER HARRY M JANSEN JRAMay 20, 2026$22.23

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$4.9B$5.6B
Gross Profit-$1.0B$1.1B
Operating Income-$321.8M$337.9M
Net Income-$211.8M$207.6M
Gross Margin-20.6%19.3%
Op. Margin-6.6%6.0%
Net Margin-4.3%3.7%
Balance Sheet
Total Assets$3.2B$3.4B$3.5B
Equity$1.4B$1.4B$1.3B
ROE-15.1%15.7%
Per Share
EPS-$1.23$1.27
Cash Flow
Operating CF-$323.4M$258.4M
CapEx-$35.6M$41.3M

Source: XBRL data in Option Care Health, Inc. (OPCH)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate OPCH share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
OPCH shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202632$1.48B
Q2 202631$1.46B
Q1 202631$1.91B
Q4 202529$2.32B
Q3 202531$2.12B
Q2 202530$2.42B
Q1 202529$1.88B
Q4 202424$998.1M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 237 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

OPCH filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 12, 2026--
10-QNov 4, 2026Analysis
8-KNov 4, 2026Analysis-
8-KOct 6, 2026Analysis-
10-QJul 29, 2026Analysis
8-KJul 29, 2026Analysis-
4Jul 8, 2026--
8-KMay 22, 2026Analysis
4May 22, 2026-
4May 22, 2026-
4May 22, 2026-
4May 22, 2026-
4May 22, 2026-
4May 22, 2026-
4May 22, 2026-
4May 22, 2026-
4May 21, 2026-
8-KMay 12, 2026Analysis
4May 7, 2026-
8-KMay 5, 2026Analysis-
4May 5, 2026--
4May 4, 2026--
4May 4, 2026--
SC 13GApr 30, 2026-
8-KApr 30, 2026Analysis-

Related Health Care companies

All Health Care →

OPCH SEC filings: frequently asked questions

Are OPCH insiders buying or selling?

In the last 90 days, Option Care Health, Inc. (OPCH) officers, directors and 10% owners reported no open-market purchases and 2 open-market sales worth $205,472 by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold OPCH stock?

As of September 30, 2026, the largest Option Care Health, Inc. (OPCH) holders among the 13F filers tracked by SignalX were BlackRock ($501.2 million), Vanguard Portfolio Management LLC ($179.2 million), Vanguard Capital Management LLC ($151.5 million), Dimensional Fund Advisors ($141.9 million), State Street Corp ($138.0 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was OPCH's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Option Care Health, Inc. (OPCH) reported revenue of $5.6 billion (up 15.0% from FY2024) and net income of $207.6 million. Diluted EPS was $1.27. The figures come from the XBRL data in the 10-K.

What did OPCH report in its latest 8-K?

Option Care Health, Inc. (OPCH) filed an 8-K on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results announced by Option Care Health on November 4, 2026.

What are the latest OPCH SEC filings?

Option Care Health, Inc. (OPCH) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and a Form 4 insider filing on November 12, 2026.

What is OPCH's SEC CIK number?

Option Care Health, Inc. (OPCH)'s SEC Central Index Key (CIK) is 1014739. EDGAR lists every OPCH filing under that number.

Ask anything about OPCH

The research agent reads OPCH's filings, financials, insider trades and 13F holders, then answers with sources.